Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): HIV diagnoses and linkage to HIV medical care, 2019 and 2020 (reported through September 2020); and preexposure prophylaxis (PrEP), 2018 (updated), 2019 and 2020 (reported through June 2020)

Advisory Statement

Effective date: May 21, 2024

Publication date of referenced document: February 2021

Preexposure prophylaxis (PrEP) coverage is currently estimated by taking the number of persons prescribed PrEP (numerator) and dividing it by the estimated number of persons with indications for PrEP (denominator). Since the current methodology for estimating PrEP coverage was first published in 2018, CDC has cited limitations of both the numerator and denominator. For example, the number of persons prescribed PrEP is estimated by using data from the IQVIA pharmacy database based on an algorithm that includes FDA-approved drugs for PrEP. Although IQVIA records 94% of all prescriptions from retail pharmacies and 74% from mail-order outlets in the United States, data from closed health care systems are not included in the IQVIA data set. Therefore, the current PrEP numerator has represented minimum estimates of PrEP prescriptions. Additionally, race/ethnicity data in the IQVIA database are only available for <40% of persons prescribed PrEP each year. Regarding limitations of the current denominator, the number of persons who have indications for PrEP is estimated by using data from 3 sources: National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Each of these data sources have different schedules of data availability. As a result, the availability of a denominator often lags the availability of a numerator.

In March 2024, updated data from 2 closed-system sources were made available to CDC that can improve the representativeness of the number of persons prescribed PrEP in the United States. In the coming months, CDC also expects to have updates to the data sets currently used to estimate the number of persons with indications for PrEP. To ensure that PrEP coverage estimates are calculated using the best available data at the time of publication, CDC is pausing PrEP coverage reporting for one year. During this time, CDC will update PrEP coverage data sources and determine the best way to present PrEP coverage. CDC plans to resume PrEP coverage reporting in the next HIV Surveillance Supplemental (Monitoring) Report, currently scheduled for publication in June 2025.

Until updated estimates are published, CDC advises against citing specific PrEP coverage data points and instead recommends referencing general trends and disparities. In addition, because of a formula error that affects a subset of race and ethnicity PrEP data, race and ethnicity data points from all reports published prior to 2024 should not be cited.

HIV SURVEILLANCE DATA TABLES

Core Indicators for Monitoring the Ending the HIV Epidemic Initiative *(Preliminary Data)*:

HIV Diagnoses and Linkage to HIV Medical Care, 2019 and 2020 (Reported through September 2020); and Preexposure Prophylaxis (PrEP), 2018 (Updated), 2019 and 2020 (Reported through June 2020)

Vol. 2, No. 1

Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV/AIDS Prevention (DHAP), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through September 2020.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): HIV diagnoses and linkage to HIV medical care, 2019 and 2020 (reported through September 2020); and preexposure prophylaxis (PrEP), 2018 (updated), 2019 and 2020 (reported through June 2020). *HIV Surveillance Data Tables* 2021;2(No. 1). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published February 2021. Accessed [date].

On the Web: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html

Confidential information, referrals, and educational material on HIV infection and AIDS

CDC-INFO
1-800-232-4636 (in English, en Español)
1-888-232-6348 (TTY)
http://wwwn.cdc.gov/dcs/ContactUs/Form

Acknowledgments

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Dawn Smith, Xiaohong Hu, Jianmin Li, Baohua Wu, Chan Jin, Shihua Wang, Weiming Zhu, Anne Patala, Lei Yu, Norma Harris, and Michael Friend and the Web and Consumer Services Team of the Prevention Communications Branch (editing and desktop publishing).

Contents

The *Ending the HIV Epidemic: A Plan for America* (EHE) initiative will leverage critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% in 5 years and by at least 90% in 10 years. Throughout the initiative, the Centers for Disease Control and Prevention (CDC) will routinely release *HIV Surveillance Data Tables* on the 6 core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core Indicators for Monitoring the Ending the HIV Epidemic Initiative* report at https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-1-no-1/index.html.

The tables included in this report provide *preliminary* data on HIV diagnoses and linkage to HIV medical care reported to CDC as of September 2020 for the years 2019 and 2020, and data on preexposure prophylaxis (PrEP) coverage for the year 2018 (updated) and for the years 2019 and 2020 (preliminary). Data for the 3 indicators are provided at the national-, state-, and county-levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated. Data reported to the National HIV Surveillance System (NHSS) are considered preliminary until a 12-month reporting lag has been reached. Because the data in this report are provided by using an NHSS dataset produced prior to reaching a 12-month reporting lag, the data should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions [2].

Tabulation and Presentation of Data

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥13 years whose HIV infection was diagnosed during January 2019 through September 2020 (Tables 1a–d).

Data presented were reported (after the removal of personally identifiable information) to CDC's NHSS through September 2020. Please use caution when interpreting data on diagnoses of HIV infection. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential, name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV infection.

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state and local jurisdictions.

More information on counting diagnoses of HIV infection can be found at https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-31/index.html (*HIV Surveillance Report, 2018 [Updated]*).

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥13 years whose HIV infection was diagnosed during January 2019 through June 2020, and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥13 years whose HIV infection was diagnosed during the specified period, and who had ≥1 CD4 or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥13 years whose HIV infection was diagnosed during the specified period. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting lag to account for delays in reporting of laboratory results to NHSS; therefore, data for the year 2020 on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January through June of 2020 and that were reported to NHSS through September 2020. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC.

Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Puerto Rico, and Vermont.

Data reported to NHSS are considered preliminary until a 12-month reporting lag has been reached; preliminary data should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

More information on calculating linkage to care can be found at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-2.pdf (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018*).

Preexposure Prophylaxis (PrEP) Coverage

PrEP coverage, reported as a percentage, is defined as the number of persons aged ≥16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥16 years who had indications for PrEP during the specified year (Tables 3a–3c).

Number of persons prescribed, which is reported as a case count, is defined as the number of persons aged ≥16 years classified as having been prescribed PrEP during the specified year.

PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage. Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data-Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 92% of all prescriptions from retail pharmacies and 60%–86% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [3–5]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Starting in 2019, TAF/FTC was included in the algorithm to estimate the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for <40% of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include white, black/African American, Hispanic/Latino, and Asian/other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [6], and (b) the U.S Department of Housing and Urban Development's ZIP Code Crosswalk Files [7]. Because of reliability concerns, subnational estimates of <40 are not included.

Persons with PrEP indications

U.S. Census Bureau datasets were used to estimate the number of men who have sex with men (MSM) in a jurisdiction. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [8].

For the 2018 denominator, this proportion was updated with recent NHANES data.

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [8]. Jurisdictional estimates were rounded to the nearest 10. Beginning in 2018, methods were adjusted to provide the estimated number of Asians and persons of other race ethnicities, in addition to Blacks/African Americans, Hispanics/Latinos, and whites.

The tables included in this report provide updated data on PrEP coverage for the year 2018 and preliminary data for the year 2019 and for the year 2020 (from January through June) using the IQVIA data reported through June 2020. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator by approximately 1 year. For this release of *HIV Surveillance Data Tables*, 2018 denominators were used for 2018, 2019, and 2020 PrEP coverage data.

REFERENCES

1. HHS. What is 'Ending the HIV Epidemic: A Plan for America'? https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. Published October 4, 2019. Accessed January 27, 2021.
2. CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. *MMWR* 2020;69(18):551–556. doi:http://dx.doi.org/10.15585/mmwr.mm6918e2
3. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017;64(2):144–149. doi:10.1093/cid/ciw701
4. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
5. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. *Public Health Rep* 2020;135(2):202–210. doi:10.1177/0033354920904085
6. U.S. Census Bureau. American Community Survey 5-year data (2009–2018). https://www.census.gov/data/developers/data-sets/acs-5year.2018.html. Published December 19, 2019. Accessed January 27, 2021.
7. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Published 2019. Accessed January 27, 2021.
8. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4

Table 1a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2019 through September 2020—United States (*preliminary*)

	2019	2020 (January–September)
	Total No.	Total No.
Gender		
Male	28,469	13,635
Female	6,784	3,191
Transgender male-to-female[a]	610	273
Transgender female-to-male[a]	42	17
Additional gender identity[b]	19	6
Age at diagnosis (yr)		
13–24	7,483	3,419
25–34	12,902	6,238
35–44	6,993	3,269
45–54	4,811	2,321
≥55	3,735	1,875
Race/ethnicity		
American Indian/Alaska Native	206	105
Asian	731	364
Black/African American	15,409	7,672
Hispanic/Latino[c]	9,574	4,131
Native Hawaiian/other Pacific Islander	65	37
White	9,055	4,525
Multiple races	884	288
Transmission category[d]		
Male-to-male sexual contact	23,724	11,552
Injection drug use		
Male	1,353	674
Female	1,094	477
Male-to-male sexual contact *and* injection drug use	1,426	553
Heterosexual contact[e]		
Male	2,558	1,115
Female	5,708	2,714
Other[f]		
Male	34	19
Female	28	18
Region of residence[g]		
Northeast	5,242	2,326
Midwest	4,725	2,255
South	18,868	9,419
West	7,089	3,122
Total	35,924	17,122

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

[a] "Transgender male-to-female" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender female-to-male" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[b] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[c] Hispanics/Latinos can be of any race.

[d] Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

[e] Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

[f] Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

[g] Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2019 through September 2020—United States and 6 dependent areas (*preliminary*)

	2019	2020 (January–September)
	Total No.	Total No.
Gender		
Male	28,789	13,766
Female	6,864	3,217
Transgender male-to-female[a]	612	274
Transgender female-to-male[a]	42	17
Additional gender identity[b]	19	6
Age at diagnosis (yr)		
13–24	7,543	3,451
25–34	13,014	6,277
35–44	7,071	3,304
45–54	4,877	2,346
≥55	3,821	1,902
Race/ethnicity		
American Indian/Alaska Native	206	105
Asian	737	364
Black/African American	15,414	7,674
Hispanic/Latino[c]	9,954	4,283
Native Hawaiian/other Pacific Islander	69	37
White	9,062	4,529
Multiple races	884	288
Transmission category[d]		
Male-to-male sexual contact	23,944	11,649
Injection drug use		
Male	1,376	687
Female	1,099	478
Male-to-male sexual contact *and* injection drug use	1,438	558
Heterosexual contact[e]		
Male	2,624	1,132
Female	5,783	2,738
Other[f]		
Male	34	19
Female	28	18
Region of residence[g]		
Northeast	5,242	2,326
Midwest	4,725	2,255
South	18,868	9,419
West	7,089	3,122
U.S. dependent areas	402	158
Total	36,326	17,280

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

[a] "Transgender male-to-female" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender female-to-male" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[b] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[c] Hispanics/Latinos can be of any race.

[d] Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

[e] Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

[f] Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

[g] Data are based on residence at time of diagnosis of HIV infection.

Table 1c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2019 through September 2020—United States and 6 dependent areas (*preliminary*)

Area of residence	2019 Total No.	2020 (January–September) Total No.
Alabama	640	346
Alaska	27	22
Arizona	765	421
Arkansas	285	193
California	4,230	1,746
Colorado	460	211
Connecticut	207	83
Delaware	93	70
District of Columbia	247	112
Florida	4,402	2,535
Georgia	2,315	1,058
Hawaii	65	23
Idaho	27	2
Illinois	1,238	441
Indiana	485	257
Iowa	100	65
Kansas	132	74
Kentucky	314	150
Louisiana	887	499
Maine	30	12
Maryland	926	441
Massachusetts	536	216
Michigan	675	370
Minnesota	274	146
Mississippi	477	270
Missouri	489	245
Montana	26	3
Nebraska	81	34
Nevada	510	156
New Hampshire	30	15
New Jersey	1,035	388
New Mexico	147	42
New York	2,332	1,127
North Carolina	1,370	748
North Dakota	36	11
Ohio	975	479
Oklahoma	309	121
Oregon	198	115
Pennsylvania	989	456
Rhode Island	72	22
South Carolina	688	466
South Dakota	33	12
Tennessee	768	428
Texas	4,176	1,452
Utah	136	96
Vermont	11	7
Virginia	827	440
Washington	485	278
West Virginia	144	90
Wisconsin	207	121
Wyoming	13	7
Subtotal	35,924	17,122
U.S. dependent areas		
American Samoa	0	0
Guam	10	0
Northern Mariana Islands	2	0
Puerto Rico	383	156
Republic of Palau	0	0
U.S. Virgin Islands	7	2
Subtotal	402	158
Total	36,326	17,280

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2019 through September 2020—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	2019 Total No.	2020 (January–September) Total No.
Arizona		
Maricopa County	517	304
California		
Alameda County	220	105
Los Angeles County	1,447	618
Orange County	246	178
Riverside County	262	127
Sacramento County	86	6
San Bernardino County	271	51
San Diego County	360	76
San Francisco County	207	103
District of Columbia	247	112
Florida		
Broward County	597	349
Duval County	272	164
Hillsborough County	268	197
Miami-Dade County	1,154	598
Orange County	470	273
Palm Beach County	237	152
Pinellas County	185	115
Georgia		
Cobb County	165	63
DeKalb County	330	136
Fulton County	552	308
Gwinnett County	195	71
Illinois		
Cook County	873	343
Indiana		
Marion County	204	103
Louisiana		
East Baton Rouge Parish	152	86
Orleans Parish	159	71
Maryland		
Baltimore City	201	99
Montgomery County	134	56
Prince George's County	279	128
Massachusetts		
Suffolk County	135	67
Michigan		
Wayne County	284	159
Nevada		
Clark County	448	126
New Jersey		
Essex County	227	101
Hudson County	147	62

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2019 through September 2020—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) *(cont)*

Area of residence	2019 Total No.	2020 (January–September) Total No.
New York		
Bronx County	500	181
Kings County	470	264
New York County	342	170
Queens County	351	186
North Carolina		
Mecklenburg County	267	138
Ohio		
Cuyahoga County	159	98
Franklin County	217	123
Hamilton County	171	65
Pennsylvania		
Philadelphia County	441	186
Puerto Rico		
San Juan Municipio	87	41
Tennessee		
Shelby County	260	159
Texas		
Bexar County	350	183
Dallas County	739	407
Harris County	1,155	225
Tarrant County	305	126
Travis County	178	79
Washington		
King County	248	139

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions.

Table 2a. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020 among persons aged ≥13 years, by selected characteristics—41 states and the District of Columbia (*preliminary*)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2019				
Gender					
Male	25,539	20,836	81.6	4,703	18.4
Female	6,018	4,828	80.2	1,190	19.8
Transgender male-to-female[a]	548	450	82.1	98	17.9
Transgender female-to-male[a]	37	33	89.2	4	10.8
Additional gender identity[b]	17	15	88.2	2	11.8
Age at diagnosis (yr)					
13–24	6,702	5,307	79.2	1,395	20.8
25–34	11,570	9,343	80.8	2,227	19.2
35–44	6,267	5,167	82.4	1,100	17.6
45–54	4,295	3,570	83.1	725	16.9
≥55	3,325	2,775	83.5	550	16.5
Race/ethnicity					
American Indian/Alaska Native	163	134	82.2	29	17.8
Asian	663	550	83.0	113	17.0
Black/African American	14,023	11,052	78.8	2,971	21.2
Hispanic/Latino[c]	8,563	7,202	84.1	1,361	15.9
Native Hawaiian/other Pacific Islander	62	51	82.3	11	17.7
White	7,878	6,509	82.6	1,369	17.4
Multiple races	807	664	82.3	143	17.7
Transmission category[d]					
Male-to-male sexual contact	21,431	17,601	82.1	3,830	17.9
Injection drug use					
Male	1,105	843	76.3	262	23.7
Female	943	713	75.6	230	24.4
Male-to-male sexual contact *and* injection drug use	1,257	1,006	80.0	251	20.0
Heterosexual contact[e]					
Male	2,277	1,823	80.1	454	19.9
Female	5,092	4,131	81.1	961	18.9
Total[f]	**32,159**	**26,162**	**81.4**	**5,997**	**18.6**

Table 2a. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020 among persons aged ≥13 years, by selected characteristics—41 states and the District of Columbia (*preliminary*) *(cont)*

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2020 (January–June)				
Gender					
Male	9,283	7,603	81.9	1,680	18.1
Female	2,198	1,796	81.7	402	18.3
Transgender male-to-female[a]	198	169	85.4	29	14.6
Transgender female-to-male[a]	7	7	100	0	0.0
Additional gender identity[b]	4	4	100	0	0.0
Age at diagnosis (yr)					
13–24	2,343	1,849	78.9	494	21.1
25–34	4,265	3,494	81.9	771	18.1
35–44	2,279	1,875	82.3	404	17.7
45–54	1,566	1,313	83.8	253	16.2
≥55	1,237	1,048	84.7	189	15.3
Race/ethnicity					
American Indian/Alaska Native	53	44	83.0	9	17.0
Asian	251	218	86.9	33	13.1
Black/African American	5,310	4,257	80.2	1,053	19.8
Hispanic/Latino[c]	2,880	2,404	83.5	476	16.5
Native Hawaiian/other Pacific Islander	24	20	83.3	4	16.7
White	2,954	2,453	83.0	501	17.0
Multiple races	218	183	83.9	35	16.1
Transmission category[d]					
Male-to-male sexual contact	7,868	6,461	82.1	1,407	17.9
Injection drug use					
Male	448	358	79.8	90	20.2
Female	334	270	80.8	64	19.2
Male-to-male sexual contact *and* injection drug use	374	306	81.9	68	18.1
Heterosexual contact[e]					
Male	783	640	81.8	142	18.2
Female	1,858	1,522	81.9	337	18.1
Total[f]	**11,690**	**9,579**	**81.9**	**2,111**	**18.1**

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through June of 2020 and are based on cases reported to CDC through September 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Puerto Rico, and Vermont.

[a] "Transgender male-to-female" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender female-to-male" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[b] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[c] Hispanics/Latinos can be of any race.

[d] Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and may include transgender persons.

[e] Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

[f] Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020 among persons aged ≥13 years, by area of residence—41 states and the District of Columbia (*preliminary*)

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2019				
Alabama	640	507	79.2	133	20.8
Alaska	27	23	85.2	4	14.8
California	4,230	3,493	82.6	737	17.4
Colorado	460	383	83.3	77	16.7
Delaware	93	71	76.3	22	23.7
District of Columbia	247	219	88.7	28	11.3
Florida	4,402	3,680	83.6	722	16.4
Georgia	2,315	1,896	81.9	419	18.1
Hawaii	65	55	84.6	10	15.4
Illinois	1,238	1,027	83.0	211	17.0
Indiana	485	303	62.5	182	37.5
Iowa	100	91	91.0	9	9.0
Louisiana	887	730	82.3	157	17.7
Maine	30	28	93.3	2	6.7
Maryland	926	808	87.3	118	12.7
Massachusetts	536	484	90.3	52	9.7
Michigan	675	568	84.1	107	15.9
Minnesota	274	252	92.0	22	8.0
Mississippi	477	338	70.9	139	29.1
Missouri	489	376	76.9	113	23.1
Montana	26	22	84.6	4	15.4
Nebraska	81	65	80.2	16	19.8
Nevada	510	426	83.5	84	16.5
New Hampshire	30	27	90.0	3	10.0
New Mexico	147	130	88.4	17	11.6
New York	2,332	2,032	87.1	300	12.9
North Carolina	1,370	1,082	79.0	288	21.0
North Dakota	36	33	91.7	3	8.3
Ohio	975	816	83.7	159	16.3
Oklahoma	309	214	69.3	95	30.7
Oregon	198	173	87.4	25	12.6
Rhode Island	72	63	87.5	9	12.5
South Carolina	688	601	87.4	87	12.6
South Dakota	33	26	78.8	7	21.2
Tennessee	768	524	68.2	244	31.8
Texas	4,176	3,102	74.3	1,074	25.7
Utah	136	105	77.2	31	22.8
Virginia	827	650	78.6	177	21.4
Washington	485	433	89.3	52	10.7
West Virginia	144	106	73.6	38	26.4
Wisconsin	207	187	90.3	20	9.7
Wyoming	13	13	100	0	0.0
Total	**32,159**	**26,162**	**81.4**	**5,997**	**18.6**

Table 2b. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020 among persons aged ≥13 years, by area of residence—41 states and the District of Columbia (*preliminary*) *(cont)*

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2020 (January–June)				
Alabama	289	232	80.3	57	19.7
Alaska	16	16	100	0	0.0
California	1,420	1,221	86.0	199	14.0
Colorado	135	119	88.1	16	11.9
Delaware	55	39	70.9	16	29.1
District of Columbia	88	80	90.9	8	9.1
Florida	1,802	1,520	84.4	282	15.6
Georgia	796	683	85.8	113	14.2
Hawaii	19	17	89.5	2	10.5
Illinois	374	326	87.2	48	12.8
Indiana	217	164	75.6	53	24.4
Iowa	44	40	90.9	4	9.1
Louisiana	331	247	74.6	84	25.4
Maine	10	9	90.0	1	10.0
Maryland	347	322	92.8	25	7.2
Massachusetts	185	157	84.9	28	15.1
Michigan	241	199	82.6	42	17.4
Minnesota	108	93	86.1	15	13.9
Mississippi	198	148	74.7	50	25.3
Missouri	174	135	77.6	39	22.4
Montana	3	2	66.7	1	33.3
Nebraska	32	27	84.4	5	15.6
Nevada	151	121	80.1	30	19.9
New Hampshire	12	11	91.7	1	8.3
New Mexico	32	28	87.5	4	12.5
New York	894	784	87.7	110	12.3
North Carolina	532	441	82.9	91	17.1
North Dakota	11	10	90.9	1	9.1
Ohio	410	366	89.3	44	10.7
Oklahoma	89	55	61.8	34	38.2
Oregon	77	68	88.3	9	11.7
Rhode Island	20	11	55.0	9	45.0
South Carolina	313	281	89.8	32	10.2
South Dakota	12	11	91.7	1	8.3
Tennessee	323	229	70.9	94	29.1
Texas	1,206	769	63.8	437	36.2
Utah	57	27	47.4	30	52.6
Virginia	306	248	81.0	58	19.0
Washington	206	189	91.7	17	8.3
West Virginia	60	47	78.3	13	21.7
Wisconsin	90	83	92.2	7	7.8
Wyoming	5	4	80.0	1	20.0
Total	**11,690**	**9,579**	**81.9**	**2,111**	**18.1**

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through June of 2020 and are based on cases reported to CDC through September 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Puerto Rico, and Vermont.

Table 2c. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2019				
California					
Alameda County	220	196	89.1	24	10.9
Los Angeles County	1,447	1,160	80.2	287	19.8
Orange County	246	199	80.9	47	19.1
Riverside County	262	211	80.5	51	19.5
Sacramento County	86	77	89.5	9	10.5
San Bernardino County	271	199	73.4	72	26.6
San Diego County	360	311	86.4	49	13.6
San Francisco County	207	199	96.1	8	3.9
District of Columbia	247	219	88.7	28	11.3
Florida					
Broward County	597	522	87.4	75	12.6
Duval County	272	209	76.8	63	23.2
Hillsborough County	268	230	85.8	38	14.2
Miami-Dade County	1,154	972	84.2	182	15.8
Orange County	470	370	78.7	100	21.3
Palm Beach County	237	187	78.9	50	21.1
Pinellas County	185	158	85.4	27	14.6
Georgia					
Cobb County	165	144	87.3	21	12.7
DeKalb County	330	271	82.1	59	17.9
Fulton County	552	464	84.1	88	15.9
Gwinnett County	195	162	83.1	33	16.9
Illinois					
Cook County	873	722	82.7	151	17.3
Indiana					
Marion County	204	107	52.5	97	47.5
Louisiana					
East Baton Rouge Parish	152	134	88.2	18	11.8
Orleans Parish	159	131	82.4	28	17.6
Maryland					
Baltimore City	201	172	85.6	29	14.4
Montgomery County	134	121	90.3	13	9.7
Prince George's County	279	247	88.5	32	11.5
Massachusetts					
Suffolk County	135	124	91.9	11	8.1
Michigan					
Wayne County	284	243	85.6	41	14.4
Nevada					
Clark County	448	371	82.8	77	17.2

Table 2c. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) *(cont)*

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2019 *(cont)*				
New York					
Bronx County	500	436	87.2	64	12.8
Kings County	470	400	85.1	70	14.9
New York County	342	303	88.6	39	11.4
Queens County	351	301	85.8	50	14.2
North Carolina					
Mecklenburg County	267	209	78.3	58	21.7
Ohio					
Cuyahoga County	159	142	89.3	17	10.7
Franklin County	217	197	90.8	20	9.2
Hamilton County	171	145	84.8	26	15.2
Pennsylvania					
Philadelphia County	441	374	84.8	67	15.2
Tennessee					
Shelby County	260	159	61.2	101	38.8
Texas					
Bexar County	350	249	71.1	101	28.9
Dallas County	739	561	75.9	178	24.1
Harris County	1,155	850	73.6	305	26.4
Tarrant County	305	226	74.1	79	25.9
Travis County	178	153	86.0	25	14.0
Washington					
King County	248	224	90.3	24	9.7

Table 2c. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) *(cont)*

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2020 (January–June)				
California					
Alameda County	87	72	82.8	15	17.2
Los Angeles County	506	438	86.6	68	13.4
Orange County	130	114	87.7	16	12.3
Riverside County	96	75	78.1	21	21.9
Sacramento County	6	4	66.7	2	33.3
San Bernardino County	48	39	81.3	9	18.8
San Diego County	75	70	93.3	5	6.7
San Francisco County	74	70	94.6	4	5.4
District of Columbia	88	80	90.9	8	9.1
Florida					
Broward County	249	214	85.9	35	14.1
Duval County	109	90	82.6	19	17.4
Hillsborough County	139	117	84.2	22	15.8
Miami-Dade County	431	361	83.8	70	16.2
Orange County	191	169	88.5	22	11.5
Palm Beach County	117	94	80.3	23	19.7
Pinellas County	82	73	89.0	9	11.0
Georgia					
Cobb County	44	37	84.1	7	15.9
DeKalb County	91	81	89.0	10	11.0
Fulton County	227	195	85.9	32	14.1
Gwinnett County	57	45	78.9	12	21.1
Illinois					
Cook County	284	249	87.7	35	12.3
Indiana					
Marion County	87	67	77.0	20	23.0
Louisiana					
East Baton Rouge Parish	63	52	82.5	11	17.5
Orleans Parish	42	32	76.2	10	23.8
Maryland					
Baltimore City	80	72	90.0	8	10.0
Montgomery County	49	47	95.9	2	4.1
Prince George's County	98	91	92.9	7	7.1
Massachusetts					
Suffolk County	57	51	89.5	6	10.5
Michigan					
Wayne County	107	87	81.3	20	18.7
Nevada					
Clark County	125	98	78.4	27	21.6

Table 2c. Linkage to HIV medical care within 1 month after HIV diagnosis during January 2019 through June 2020 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) *(cont)*

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
	2020 (January–June) *(cont)*				
New York					
Bronx County	144	125	86.8	19	13.2
Kings County	212	179	84.4	33	15.6
New York County	136	114	83.8	22	16.2
Queens County	144	132	91.7	12	8.3
North Carolina					
Mecklenburg County	90	74	82.2	16	17.8
Ohio					
Cuyahoga County	82	77	93.9	5	6.1
Franklin County	95	84	88.4	11	11.6
Hamilton County	60	55	91.7	5	8.3
Pennsylvania					
Philadelphia County	135	114	84.4	21	15.6
Tennessee					
Shelby County	126	80	63.5	46	36.5
Texas					
Bexar County	140	75	53.6	65	46.4
Dallas County	302	195	64.6	107	35.4
Harris County	207	138	66.7	69	33.3
Tarrant County	105	66	62.9	39	37.1
Travis County	70	43	61.4	27	38.6
Washington					
King County	96	90	93.8	6	6.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2020, are considered preliminary until a 12-month reporting lag has been reached, and should be interpreted with caution. In addition to being preliminary, data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV case surveillance activities in state/local jurisdictions. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a 3-month reporting lag to account for delays in reporting of laboratory results to CDC; therefore, data for the year 2020 on linkage to HIV medical care are for persons with HIV diagnosed during January through June of 2020 and are based on cases reported to CDC through September 2020. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: New Jersey and Pennsylvania (excluding Philadelphia County). Areas with incomplete lab reporting: Arizona and Puerto Rico.

Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020 among persons aged ≥16 years, by selected characteristics—United States (*updated data for 2018; preliminary data for 2019, 2020*)

	Persons prescribed PrEP[a]	Persons with PrEP indications[b]	PrEP coverage[c]
	No.	No.	%
	2018		
Sex			
Male	204,863	989,200	20.7
Female	15,688	227,010	6.9
Age (yr)			
13–24	29,413	246,290	11.9
25–34	90,975	434,680	20.9
35–44	50,892	238,470	21.3
45–54	31,602	173,420	18.2
≥55	17,780	123,350	14.4
Race/ethnicity[d]			
Asian/other	9,510	131,180	7.2
Black/African American	28,732	468,540	6.1
Hispanic/Latino	33,450	312,820	10.7
White	148,971	300,650	49.5
Total	**220,662**	**1,216,210**	**18.1**
	2019		
Sex			
Male	256,873	989,200	26.0
Female	21,697	227,010	9.6
Age (yr)			
13–24	38,033	246,290	15.4
25–34	114,188	434,680	26.3
35–44	64,308	238,470	27.0
45–54	37,529	173,420	21.6
≥55	24,660	123,350	20.0
Race/ethnicity[d]			
Asian/other	11,698	131,180	8.9
Black/African American	37,703	468,540	8.0
Hispanic/Latino	42,999	312,820	13.7
White	186,318	300,650	62.0
Total	**278,718**	**1,216,210**	**22.9**

Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020 among persons aged ≥16 years, by selected characteristics—United States (*updated data for 2018; preliminary data for 2019, 2020*) *(cont)*

	Persons prescribed PrEP[a]	Persons with PrEP indications[b]	PrEP coverage[c]
	No.	No.	%
	2020 (January–June)		
Sex			
Male	213,871	989,200	21.6
Female	15,992	227,010	7.0
Age (yr)			
13–24	23,998	246,290	9.7
25–34	90,230	434,680	20.8
35–44	57,427	238,470	24.1
45–54	33,282	173,420	19.2
≥55	25,006	123,350	20.3
Race/ethnicity[d]			
Asian/other	9,399	131,180	7.2
Black/African American	30,378	468,540	6.5
Hispanic/Latino	35,264	312,820	11.3
White	154,901	300,650	51.5
Total	**229,943**	**1,216,210**	**18.9**

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; CDC, the Centers for Disease Control and Prevention [footnotes only].

[a] Estimated by using data from IQVIA pharmacy database reported through June 2020 and based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; therefore, values may not sum to column total.

[b] Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; therefore, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2018, 2019, and 2020 PrEP coverage data.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

[d] Race/ethnicity data were only available for <40% of persons prescribed PrEP each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020 among persons aged ≥16 years, by area of residence—United States and Puerto Rico (*updated data for 2018; preliminary data for 2019, 2020*)

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
		2018	
Alabama	1,531	11,020	13.9
Alaska	196	1,780	11.0
Arizona	3,531	25,780	13.7
Arkansas	610	5,130	11.9
California	36,360	165,030	22.0
Colorado	3,416	25,120	13.6
Connecticut	2,315	9,560	24.2
Delaware	413	4,400	9.4
District of Columbia	5,045	12,950	39.0
Florida	14,621	125,330	11.7
Georgia	6,318	39,030	16.2
Hawaii	686	4,360	15.7
Idaho	368	4,790	7.7
Illinois	13,935	55,860	24.9
Indiana	2,184	22,170	9.9
Iowa	1,171	4,760	24.6
Kansas	740	5,060	14.6
Kentucky	1,213	12,990	9.3
Louisiana	3,490	15,920	21.9
Maine	481	3,950	12.2
Maryland	3,997	27,300	14.6
Massachusetts	8,029	24,900	32.2
Michigan	3,511	29,570	11.9
Minnesota	3,498	21,720	16.1
Mississippi	647	4,530	14.3
Missouri	2,779	18,370	15.1
Montana	183	2,290	8.0
Nebraska	474	2,180	21.7
Nevada	1,514	11,390	13.3
New Hampshire	506	3,020	16.8
New Jersey	4,667	25,280	18.5
New Mexico	805	6,800	11.8
New York	30,291	72,640	41.7
North Carolina	3,981	32,490	12.3
North Dakota	164	1,520	10.8
Ohio	4,793	40,320	11.9
Oklahoma	830	11,030	7.5
Oregon	2,730	19,750	13.8
Pennsylvania	8,652	36,490	23.7
Puerto Rico	236	9,700	2.4
Rhode Island	871	3,880	22.4
South Carolina	1,243	10,390	12.0
South Dakota	97	910	10.7
Tennessee	2,614	22,460	11.6
Texas	17,672	123,790	14.3
Utah	1,485	6,840	21.7
Vermont	285	1,060	26.9
Virginia	3,183	31,430	10.1
Washington	8,667	40,050	21.6
West Virginia	376	5,250	7.2
Wisconsin	1,979	12,980	15.2
Wyoming	75	890	8.4

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020 among persons aged ≥16 years, by area of residence—United States and Puerto Rico (*updated data for 2018; preliminary data for 2019, 2020*) *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
		2019	
Alabama	1,882	11,020	17.1
Alaska	235	1,780	13.2
Arizona	4,654	25,780	18.1
Arkansas	776	5,130	15.1
California	42,775	165,030	25.9
Colorado	4,331	25,120	17.2
Connecticut	2,768	9,560	29.0
Delaware	477	4,400	10.8
District of Columbia	5,941	12,950	45.9
Florida	22,062	125,330	17.6
Georgia	8,774	39,030	22.5
Hawaii	848	4,360	19.4
Idaho	478	4,790	10.0
Illinois	16,788	55,860	30.1
Indiana	3,044	22,170	13.7
Iowa	1,456	4,760	30.6
Kansas	929	5,060	18.4
Kentucky	1,642	12,990	12.6
Louisiana	4,137	15,920	26.0
Maine	648	3,950	16.4
Maryland	5,129	27,300	18.8
Massachusetts	10,060	24,900	40.4
Michigan	4,541	29,570	15.4
Minnesota	4,258	21,720	19.6
Mississippi	949	4,530	20.9
Missouri	3,565	18,370	19.4
Montana	269	2,290	11.7
Nebraska	630	2,180	28.9
Nevada	2,205	11,390	19.4
New Hampshire	639	3,020	21.2
New Jersey	5,865	25,280	23.2
New Mexico	1,089	6,800	16.0
New York	35,640	72,640	49.1
North Carolina	5,486	32,490	16.9
North Dakota	202	1,520	13.3
Ohio	6,259	40,320	15.5
Oklahoma	1,210	11,030	11.0
Oregon	3,361	19,750	17.0
Pennsylvania	10,399	36,490	28.5
Puerto Rico	336	9,700	3.5
Rhode Island	1,111	3,880	28.6
South Carolina	1,780	10,390	17.1
South Dakota	148	910	16.3
Tennessee	3,949	22,460	17.6
Texas	23,490	123,790	19.0
Utah	2,008	6,840	29.4
Vermont	343	1,060	32.4
Virginia	4,565	31,430	14.5
Washington	10,496	40,050	26.2
West Virginia	600	5,250	11.4
Wisconsin	2,647	12,980	20.4
Wyoming	93	890	10.4

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020 among persons aged ≥16 years, by area of residence—United States and Puerto Rico (*updated data for 2018; preliminary data for 2019, 2020*) *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2020 (January–June)		
Alabama	1,542	11,020	14.0
Alaska	194	1,780	10.9
Arizona	3,944	25,780	15.3
Arkansas	636	5,130	12.4
California	33,998	165,030	20.6
Colorado	3,518	25,120	14.0
Connecticut	1,959	9,560	20.5
Delaware	371	4,400	8.4
District of Columbia	4,929	12,950	38.1
Florida	23,393	125,330	18.7
Georgia	7,452	39,030	19.1
Hawaii	698	4,360	16.0
Idaho	476	4,790	9.9
Illinois	12,801	55,860	22.9
Indiana	2,373	22,170	10.7
Iowa	1,133	4,760	23.8
Kansas	699	5,060	13.8
Kentucky	1,251	12,990	9.6
Louisiana	2,861	15,920	18.0
Maine	488	3,950	12.4
Maryland	3,905	27,300	14.3
Massachusetts	8,171	24,900	32.8
Michigan	3,610	29,570	12.2
Minnesota	3,324	21,720	15.3
Mississippi	716	4,530	15.8
Missouri	2,884	18,370	15.7
Montana	228	2,290	10.0
Nebraska	539	2,180	24.7
Nevada	1,758	11,390	15.4
New Hampshire	491	3,020	16.3
New Jersey	4,578	25,280	18.1
New Mexico	903	6,800	13.3
New York	27,212	72,640	37.5
North Carolina	4,625	32,490	14.2
North Dakota	157	1,520	10.3
Ohio	5,182	40,320	12.9
Oklahoma	1,089	11,030	9.9
Oregon	2,728	19,750	13.8
Pennsylvania	8,361	36,490	22.9
Puerto Rico	278	9,700	2.9
Rhode Island	907	3,880	23.4
South Carolina	1,559	10,390	15.0
South Dakota	105	910	11.5
Tennessee	3,678	22,460	16.4
Texas	20,464	123,790	16.5
Utah	1,758	6,840	25.7
Vermont	241	1,060	22.7
Virginia	3,945	31,430	12.6
Washington	9,091	40,050	22.7
West Virginia	405	5,250	7.7
Wisconsin	2,018	12,980	15.5
Wyoming	67	890	7.5

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; CDC, the Centers for Disease Control and Prevention [footnotes only].

[a] Estimated by using data from IQVIA pharmacy database reported through June 2020 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; therefore, values may not sum to column total.

[b] Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; therefore, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2018, 2019, and 2020 PrEP coverage data.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*updated data for 2018; preliminary data for 2019, 2020*)

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2018		
Arizona			
Maricopa County	2,835	22,720	12.5
California			
Alameda County	1,877	8,930	21.0
Los Angeles County	12,287	67,450	18.2
Orange County	1,628	10,510	15.5
Riverside County	1,356	11,080	12.2
Sacramento County	790	5,920	13.3
San Bernardino County	601	11,890	5.1
San Diego County	3,395	14,500	23.4
San Francisco County	7,912	10,840	73.0
District of Columbia	5,045	12,950	39.0
Florida			
Broward County	2,786	20,470	13.6
Duval County	375	8,970	4.2
Hillsborough County	1,118	12,910	8.7
Miami-Dade County	3,824	21,760	17.6
Orange County	1,870	15,310	12.2
Palm Beach County	576	9,170	6.3
Pinellas County	781	9,530	8.2
Georgia			
Cobb County	383	3,070	12.5
DeKalb County	1,188	6,290	18.9
Fulton County	2,574	13,120	19.6
Gwinnett County	455	3,240	14.0
Illinois			
Cook County	11,471	39,060	29.4
Indiana			
Marion County	853	9,150	9.3
Louisiana			
East Baton Rouge Parish	442	1,810	24.4
Orleans Parish	1,358	4,590	29.6
Maryland			
Baltimore City	651	6,330	10.3
Montgomery County	797	5,770	13.8
Prince George's County	645	4,040	16.0
Massachusetts			
Suffolk County	2,488	6,520	38.2
Michigan			
Wayne County	1,035	9,270	11.2
Nevada			
Clark County	1,277	11,670	10.9
New Jersey			
Essex County	591	4,090	14.4
Hudson County	858	4,650	18.5

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*updated data for 2018; preliminary data for 2019, 2020*) *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2018 *(cont)*		
New York			
Bronx County	2,030	5,570	36.4
Kings County	6,278	15,650	40.1
New York County	12,276	15,540	79.0
Queens County	3,336	9,230	36.1
North Carolina			
Mecklenburg County	957	8,450	11.3
Ohio			
Cuyahoga County	819	7,520	10.9
Franklin County	1,622	11,620	14.0
Hamilton County	441	7,720	5.7
Pennsylvania			
Philadelphia County	3,237	9,840	32.9
Puerto Rico			
San Juan Municipio	—[d]	2,190	n/a
Tennessee			
Shelby County	466	6,450	7.2
Texas			
Bexar County	1,114	11,920	9.3
Dallas County	3,251	28,670	11.3
Harris County	3,873	40,670	9.5
Tarrant County	1,179	11,340	10.4
Travis County	3,414	11,590	29.5
Washington			
King County	6,112	17,890	34.2

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*updated data for 2018; preliminary data for 2019, 2020*) *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2019		
Arizona			
Maricopa County	3,591	22,720	15.8
California			
Alameda County	2,217	8,930	24.8
Los Angeles County	14,196	67,450	21.0
Orange County	2,114	10,510	20.1
Riverside County	1,754	11,080	15.8
Sacramento County	978	5,920	16.5
San Bernardino County	770	11,890	6.5
San Diego County	3,877	14,500	26.7
San Francisco County	8,886	10,840	82.0
District of Columbia	5,941	12,950	45.9
Florida			
Broward County	3,754	20,470	18.3
Duval County	517	8,970	5.8
Hillsborough County	1,459	12,910	11.3
Miami-Dade County	6,607	21,760	30.4
Orange County	2,827	15,310	18.5
Palm Beach County	892	9,170	9.7
Pinellas County	1,108	9,530	11.6
Georgia			
Cobb County	571	3,070	18.6
DeKalb County	1,573	6,290	25.0
Fulton County	3,308	13,120	25.2
Gwinnett County	698	3,240	21.5
Illinois			
Cook County	13,682	39,060	35.0
Indiana			
Marion County	1,149	9,150	12.6
Louisiana			
East Baton Rouge Parish	509	1,810	28.1
Orleans Parish	1,635	4,590	35.6
Maryland			
Baltimore City	918	6,330	14.5
Montgomery County	961	5,770	16.7
Prince George's County	835	4,040	20.7
Massachusetts			
Suffolk County	3,136	6,520	48.1
Michigan			
Wayne County	1,289	9,270	13.9
Nevada			
Clark County	1,888	11,670	16.2
New Jersey			
Essex County	708	4,090	17.3
Hudson County	1,070	4,650	23.0

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*updated data for 2018; preliminary data for 2019, 2020*) *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2019 *(cont)*		
New York			
Bronx County	2,302	5,570	41.3
Kings County	7,503	15,650	47.9
New York County	14,172	15,540	91.2
Queens County	3,965	9,230	43.0
North Carolina			
Mecklenburg County	1,372	8,450	16.2
Ohio			
Cuyahoga County	988	7,520	13.1
Franklin County	2,060	11,620	17.7
Hamilton County	559	7,720	7.2
Pennsylvania			
Philadelphia County	3,719	9,840	37.8
Puerto Rico			
San Juan Municipio	—[d]	2,190	n/a
Tennessee			
Shelby County	645	6,450	10.0
Texas			
Bexar County	1,491	11,920	12.5
Dallas County	4,221	28,670	14.7
Harris County	4,957	40,670	12.2
Tarrant County	1,497	11,340	13.2
Travis County	4,608	11,590	39.8
Washington			
King County	7,373	17,890	41.2

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*updated data for 2018; preliminary data for 2019, 2020*) *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2020 (January–June)		
Arizona			
Maricopa County	3,063	22,720	13.5
California			
Alameda County	1,653	8,930	18.5
Los Angeles County	11,747	67,450	17.4
Orange County	1,737	10,510	16.5
Riverside County	1,469	11,080	13.3
Sacramento County	758	5,920	12.8
San Bernardino County	589	11,890	5.0
San Diego County	3,083	14,500	21.3
San Francisco County	6,908	10,840	63.7
District of Columbia	4,929	12,950	38.1
Florida			
Broward County	4,540	20,470	22.2
Duval County	504	8,970	5.6
Hillsborough County	1,187	12,910	9.2
Miami-Dade County	7,290	21,760	33.5
Orange County	2,764	15,310	18.1
Palm Beach County	1,525	9,170	16.6
Pinellas County	897	9,530	9.4
Georgia			
Cobb County	496	3,070	16.2
DeKalb County	1,339	6,290	21.3
Fulton County	2,798	13,120	21.3
Gwinnett County	608	3,240	18.8
Illinois			
Cook County	10,452	39,060	26.8
Indiana			
Marion County	906	9,150	9.9
Louisiana			
East Baton Rouge Parish	394	1,810	21.8
Orleans Parish	1,092	4,590	23.8
Maryland			
Baltimore City	720	6,330	11.4
Montgomery County	728	5,770	12.6
Prince George's County	637	4,040	15.8
Massachusetts			
Suffolk County	2,664	6,520	40.9
Michigan			
Wayne County	956	9,270	10.3
Nevada			
Clark County	1,482	11,670	12.7
New Jersey			
Essex County	528	4,090	12.9
Hudson County	847	4,650	18.2

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2018 through June 2020 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*updated data for 2018; preliminary data for 2019, 2020*) *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2020 (January–June) *(cont)*		
New York			
Bronx County	1,546	5,570	27.8
Kings County	5,705	15,650	36.5
New York County	11,199	15,540	72.1
Queens County	3,010	9,230	32.6
North Carolina			
Mecklenburg County	1,219	8,450	14.4
Ohio			
Cuyahoga County	738	7,520	9.8
Franklin County	1,794	11,620	15.4
Hamilton County	462	7,720	6.0
Pennsylvania			
Philadelphia County	2,762	9,840	28.1
Puerto Rico			
San Juan Municipio	—[d]	2,190	n/a
Tennessee			
Shelby County	598	6,450	9.3
Texas			
Bexar County	1,231	11,920	10.3
Dallas County	3,852	28,670	13.4
Harris County	4,531	40,670	11.1
Tarrant County	1,182	11,340	10.4
Travis County	3,931	11,590	33.9
Washington			
King County	6,515	17,890	36.4

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; CDC, the Centers for Disease Control and Prevention [footnotes only].

[a] Estimated by using data from IQVIA pharmacy database reported through June 2020 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; therefore, values may not sum to column total.

[b] Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; therefore, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2018, 2019, and 2020 PrEP coverage data.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

[d] Data value <40 was not reported due to unreliability.